Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans—a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST)

BACKGROUND: Betahistine was registered in Europe in the 1970s and approved in more than 80 countries as a first-line treatment for Menière's disease. It has been administered to more than 150 million patients. However, according to a Cochrane systematic review of betahistine and recent meta-ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Strupp, Michael, Churchill, Grant C., Naumann, Ivonne, Mansmann, Ulrich, Al Tawil, Amani, Golentsova, Anastasia, Goldschagg, Nicolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619746/
https://www.ncbi.nlm.nih.gov/pubmed/37920833
http://dx.doi.org/10.3389/fneur.2023.1271640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619746/
https://www.ncbi.nlm.nih.gov/pubmed/37920833
http://dx.doi.org/10.3389/fneur.2023.1271640

Ejemplares similares